Patents by Inventor Joel H. Martin
Joel H. Martin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11820815Abstract: The present invention provides methods of treating, ameliorating, or inhibiting tumor growth, cancer, or pathological angiogenesis by administering to a subject in need thereof a human antibody or fragment thereof that specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The anti-hDll4 antibody or fragment thereof of the present invention have a high affinity with the KD of 500 pM or less, as measured by surface plasmon resonance.Type: GrantFiled: June 4, 2020Date of Patent: November 21, 2023Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Nicholas J. Papadopoulos, Joel H. Martin, Eric Smith, Irene Noguera-Troise, Gavin Thurston
-
Publication number: 20230345919Abstract: Non-human animal cells and non-human animals comprising a humanized Asgr1 locus and methods of using such non-human animal cells and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized Asgr1 locus express a human ASGR1 protein or an Asgr1 protein, fragments of which are from human ASGR1. Methods are provided for using such non-human animals comprising a humanized Asgr1 locus to assess in vivo efficacy of human-ASGR1-mediated delivery of therapeutic molecules or therapeutic complexes to the liver and to assess the efficacy of therapeutic molecules or therapeutic complexes acting via human-ASGR1-mediated mechanisms.Type: ApplicationFiled: May 19, 2023Publication date: November 2, 2023Inventors: Alexander O. Mujica, Viktoria Gusarova, Cheng Wang, Christos Kyratsous, Terra Potocky, Katherine Cygnar, Joel H. Martin
-
Publication number: 20230340153Abstract: An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements.Type: ApplicationFiled: April 5, 2023Publication date: October 26, 2023Inventors: Mark W. SLEEMAN, Joel H. MARTIN, Tammy T. HUANG, Douglas MACDONALD
-
Patent number: 11696572Abstract: Non-human animal cells and non-human animals comprising a humanized Asgr1 locus and methods of using such non-human animal cells and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized Asgr1 locus express a human ASGR1 protein or an Asgr1 protein, fragments of which are from human ASGR1. Methods are provided for using such non-human animals comprising a humanized Asgr1 locus to assess in vivo efficacy of human-ASGR1-mediated delivery of therapeutic molecules or therapeutic complexes to the liver and to assess the efficacy of therapeutic molecules or therapeutic complexes acting via human-ASGR1-mediated mechanisms.Type: GrantFiled: June 27, 2018Date of Patent: July 11, 2023Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Alexander O. Mujica, Viktoria Gusarova, Cheng Wang, Christos Kyratsous, Terra Potocky, Katherine Cygnar, Joel H. Martin
-
Publication number: 20230094591Abstract: A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.Type: ApplicationFiled: May 20, 2022Publication date: March 30, 2023Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
-
Patent number: 11608380Abstract: The present invention provides antibodies that bind to the class Ill variant of EGFR (EGFRvIII) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human EGFRvIII with high affinity. The antibodies of the invention may be fully human antibodies. The invention includes anti-EGFRvIII antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers.Type: GrantFiled: July 1, 2020Date of Patent: March 21, 2023Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Jessica R. Kirshner, Douglas MacDonald, Gavin Thurston, Joel H. Martin, Frank Delfino, Thomas Nittoli, Marcus Kelly
-
Patent number: 11518804Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.Type: GrantFiled: July 10, 2020Date of Patent: December 6, 2022Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Lynn MacDonald, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt, Paul Tiseo
-
Publication number: 20220217955Abstract: Genetically modified non-human animals are provided that express an immunoglobulin variable domain that comprises at least one histidine, wherein the at least one histidine is encoded by a substitution of a non-histidine codon in the germline of the animal with a histidine codon, or the insertion of a histidine codon in a germline immunoglobulin nucleic acid sequence. Immunoglobulin genes comprising histidines in one or more CDRs, in an N-terminal region, and/or in a loop 4 region are also provided. Immunoglobulin variable domains comprising one or more histidines (e.g., histidine clusters) substituted for non-antigen-binding non-histidine residues. Non-human animals that are progeny of animals comprising modified heavy chain variable loci (V, D, J segments), modified light chain variable loci (V, J segments), and rearranged germline light chain genes (VJ sequences) are also provided. Non-human animals that make immunoglobulin domains that bind antigens in a pH-sensitive manner are provided.Type: ApplicationFiled: December 8, 2021Publication date: July 14, 2022Inventors: John McWhirter, Lynn Macdonald, Joel H. Martin, Andrew J. Murphy
-
Patent number: 11370843Abstract: A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.Type: GrantFiled: January 28, 2020Date of Patent: June 28, 2022Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
-
Publication number: 20220025030Abstract: The present invention provides methods of treating, ameliorating, or inhibiting tumor growth, cancer, or pathological angiogenesis by administering to a subject in need thereof a human antibody or fragment thereof that specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The anti-hDll4 antibody or fragment thereof of the present invention have a high affinity with the KD of 500 pM or less, as measured by surface plasmon resonance.Type: ApplicationFiled: June 4, 2020Publication date: January 27, 2022Inventors: Nicholas J. Papadopoulos, Joel H. Martin, Eric Smith, Irene Noguera-Troise, Gavin Thurston
-
Patent number: 11224207Abstract: Genetically modified non-human animals are provided that express an immunoglobulin variable domain that comprises at least one histidine, wherein the at least one histidine is encoded by a substitution of a non-histidine codon in the germline of the animal with a histidine codon, or the insertion of a histidine codon in a germline immunoglobulin nucleic acid sequence. Immunoglobulin genes comprising histidines in one or more CDRs, in an N-terminal region, and/or in a loop 4 region are also provided. Immunoglobulin variable domains comprising one or more histidines (e.g., histidine clusters) substituted for non-antigen-binding non-histidine residues. Non-human animals that are progeny of animals comprising modified heavy chain variable loci (V, D, J segments), modified light chain variable loci (V, J segments), and rearranged germline light chain genes (VJ sequences) are also provided. Non-human animals that make immunoglobulin domains that bind antigens in a pH-sensitive manner are provided.Type: GrantFiled: September 13, 2017Date of Patent: January 18, 2022Assignee: Regeneran Pharmaceuticals, Inc.Inventors: John McWhirter, Lynn Macdonald, Joel H. Martin, Andrew J. Murphy
-
Publication number: 20210253735Abstract: An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements.Type: ApplicationFiled: January 28, 2021Publication date: August 19, 2021Inventors: Mark W. SLEEMAN, Joel H. MARTIN, Tammy T. HUANG, Douglas MACDONLAD
-
Publication number: 20210163611Abstract: The present invention provides nucleic acid molecules that encode antibodies or antigen-binding fragments thereof, which specifically bind human interleukin-4 receptor (lL-4R). Also provided are expression vectors comprising nucleic acid molecule that encode anti-lL-4R antibodies, host cells comprising the expression vectors, and methods of producing anti-lL-4R antibodies or antigen-binding fragments thereof comprising growing the host cells under conditions permitting production of the antibody or fragment, and recovering the antibody or fragment so produced.Type: ApplicationFiled: October 6, 2020Publication date: June 3, 2021Inventors: Joel H. MARTIN, Tammy T. HUANG, Jeanette L. FAIRHURST, Nicholas J. PAPADOPOULOS, George D. YANCOPOULOS
-
Publication number: 20210147557Abstract: The present invention provides antibodies that bind to the class Ill variant of EGFR (EGFRvIII) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human EGFRvIII with high affinity. The antibodies of the invention may be fully human antibodies. The invention includes anti-EGFRvIII antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers.Type: ApplicationFiled: July 1, 2020Publication date: May 20, 2021Inventors: Jessica R. KIRSHNER, Douglas MACDONALD, Gavin THURSTON, Joel H. MARTIN, Frank DELFINO, Thomas NITTOLI, Marcus KELLY
-
Patent number: 10941210Abstract: An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements.Type: GrantFiled: June 4, 2018Date of Patent: March 9, 2021Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Mark W. Sleeman, Joel H. Martin, Tammy T. Huang, Douglas Macdonald
-
Publication number: 20210009698Abstract: A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.Type: ApplicationFiled: January 28, 2020Publication date: January 14, 2021Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow
-
Publication number: 20200339672Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.Type: ApplicationFiled: July 10, 2020Publication date: October 29, 2020Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Lynn MACDONALD, Richard TORRES, Marc R. MORRA, Joel H. MARTIN, Joel C. REINHARDT, Paul TISEO
-
Patent number: 10745471Abstract: Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved.Type: GrantFiled: February 21, 2019Date of Patent: August 18, 2020Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Lynn MacDonald, Richard Torres, Marc R. Morra, Joel H. Martin, Joel C. Reinhardt, Paul Tiseo
-
Patent number: 10738124Abstract: The present invention provides antibodies that bind to the class III variant of EGFR (EGFRvIII) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human EGFRvIII with high affinity. The antibodies of the invention may be fully human antibodies. The invention includes anti-EGFRvIII antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers.Type: GrantFiled: July 12, 2018Date of Patent: August 11, 2020Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Jessica R. Kirshner, Douglas MacDonald, Gavin Thurston, Joel H. Martin, Frank Delfino, Thomas Nittoli, Marcus Kelly
-
Patent number: 10584173Abstract: A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.Type: GrantFiled: August 31, 2018Date of Patent: March 10, 2020Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Sean Stevens, Tammy T. Huang, Joel H. Martin, Jeanette L. Fairhurst, Ashique Rafique, Eric Smith, Kevin J. Pobursky, Nicholas J. Papadopoulos, James P. Fandl, Gang Chen, Margaret Karow